Trastuzumab (anti-HER2)

目录号：A2007         批次号: A200708

打印

Trastuzumab (anti-HER2)曲妥珠单抗是人源重组的抗体抑制剂，与HER2的胞外区域相结合。 MW:145.53 KD。

抗体信息

CAS号 180288-69-1
配制 PBS buffer, pH 7.2
推荐同型对照 Human IgG1
来源 CHO cells
储存条件
(自收到货起)		 Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles
纯度 99%
蛋白浓度 7.49 mg/ml
内毒素 ＜1EU/mg

客户使用selleck产品的实验数据

Trastuzumab (anti-HER2)在文献中得到引用

Identification of a novel potent CDK inhibitor degrading cyclinK with a superb activity to reverse trastuzumab-resistance in HER2-positive breast cancer in vivo [ Eur J Med Chem, 2024, 264:116014] PubMed: 38061230
Neddylation of HER2 Inhibits its Protein Degradation and promotes Breast Cancer Progression [ Int J Biol Sci, 2023, 19(2):377-392] PubMed: 36632463
Irreversible HER2 inhibitors overcome resistance to the RSL3 ferroptosis inducer in non-HER2 amplified luminal breast cancer [ Cell Death Dis, 2023, 14(8):532] PubMed: 37596261
Detecting Disruption of HER2 Membrane Protein Organization in Cell Membranes with Nanoscale Precision [ ACS Sens, 2023, 10.1021/acssensors.3c01437] PubMed: 37955934
T lymphocytes expressing the switchable chimeric Fc receptor CD64 exhibit augmented persistence and antitumor activity [ Cell Rep, 2023, 42(7):112797] PubMed: 37436890
Engineering choroid plexus-on-a-chip with oscillatory flow for modeling brain metastasis [ Mater Today Bio, 2023, 22:100773] PubMed: 37664794
Multi-Targeting Anticancer Activity of a New 4-Thiazolidinone Derivative with Anti-HER2 Antibodies in Human AGS Gastric Cancer Cells [ Int J Mol Sci, 2023, 24(7)6791] PubMed: 37047765
The effect of the alpha-specific PI3K inhibitor alpelisib combined with anti-HER2 therapy in HER2+/PIK3CA mutant breast cancer [ Front Oncol, 2023, 13:1108242] PubMed: 37469415
Immune suppressive signaling regulated by latent transforming growth factor beta binding protein 1 promotes metastasis in cervical cancer [ Braz J Med Biol Res, 2023, 55:e12206] PubMed: 36629522
Generation and Integrated Analysis of Advanced Patient-Derived Orthoxenograft Models (PDOX) for the Rational Assessment of Targeted Therapies in Endometrial Cancer [ Adv Sci (Weinh), 2022, e2204211] PubMed: 36373729

禁止用于人体及治疗！